All stock lists
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.64+$0.01 (+2.17%)
Market cap
$38.9M
Insider Score
Health Score
Analyst consensus
Listed since
May 2, 2014
Website
Insider Score
91/ 100
ALDX Insider Score
Bullish2 qualifying trades · 2 insiders · $135.40K bought in the last 90 days
Financial Health Score
Sound
From ALDX’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$19.1M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $458.70B
- Cash
- $40974.98B
- Debt / equity
- 0.01
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $42918.80B
- Current liabilities
- $7879.58B
- Current ratio
- 5.45
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$19.1M
- Free cash flow
- -$19.1M
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 60.4M
- Share growth (1y)
- 0.4%
- Cash runway
- 25712002 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ALDX Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | $0.00 | $0.00 | $66.60 K | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | -$66.60 K | $0.00 | $0.00 | $0.00 |
| SG&A Expense | $2.30 M | $2.37 M | $1137.34 B | $2.36 M | $2.57 M | $1.66 M |
| R&D Expense | $1.84 M | $3.48 M | $2.41 M | $4.30 M | $5.43 M | $8.51 M |
| Operating Expenses | $4.14 M | $5.85 M | $3.48 M | $6.67 M | $8.00 M | $10.17 M |
| Operating Income | -$4.14 M | -$5.85 M | -$3.55 M | -$6.67 M | -$8.00 M | -$10.17 M |
| Pretax Income | -$3.76 M | -$5.45 M | -$3.45 M | -$6.46 M | -$7.69 M | -$9.77 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.76 M | -$5.45 M | -$3.45 M | -$6.46 M | -$7.69 M | -$9.77 M |
| EPS (Basic) | -$0.06 | -$0.09 | -$0.06 | -$0.11 | -$0.13 | -$0.16 |
| EPS (Diluted) | -$0.06 | -$0.09 | -$0.06 | -$0.11 | -$0.13 | -$0.16 |
| Shares Outstanding | 60.35 M | 60.32 M | 60.32 M | 60.16 M | 60.13 M | 60.05 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.